Benchmarking the Vendor Qualification Process.

Outsourcing Procurement Vendor evaluation Vendor qualification

Journal

Therapeutic innovation & regulatory science
ISSN: 2168-4804
Titre abrégé: Ther Innov Regul Sci
Pays: Switzerland
ID NLM: 101597411

Informations de publication

Date de publication:
11 2020
Historique:
received: 06 03 2020
accepted: 24 04 2020
entrez: 1 12 2020
pubmed: 2 12 2020
medline: 4 6 2021
Statut: ppublish

Résumé

The vendor qualification assessment (VQA) process is regarded as expensive and time consuming but there is no quantitative data characterizing and benchmarking this process. The Tufts Center for the Study of Drug Development (Tufts CSDD)-in collaboration with the Avoca Group and 13 pharmaceutical, biotechnology and contract research organizations-conducted a survey of 120 unique companies to gather baseline data. The study results confirm that companies are investing substantial time and resources to support a high and growing volume of vendor qualifications and re-qualifications each year. The average total time to perform a vendor qualification is almost 5 months for single service providers and nearly 7 months for multi-service providers with wide variation within and between companies observed. Re-qualification cycle times are only marginally faster although, in theory, experience and familiarity with a given vendor should replace some assessment requirements. Significant differences were observed by company size and type. A high percentage of assessments-most notably those conducted by large companies-involve customized assessment areas. CROs are able to perform the VQA process significantly faster with fewer personnel. Based on the data provided, Tufts CSDD estimates that global drug developers spent about $375 million to perform approximately 25,000 new vendor qualifications and re-qualifications in 2018.

Identifiants

pubmed: 33258097
doi: 10.1007/s43441-020-00157-9
pii: 10.1007/s43441-020-00157-9
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1349-1358

Auteurs

Kenneth Getz (K)

Tufts Center for the Study of Drug Development, Tufts University School of Medicine, 75 Kneeland Street, 11th Floor, Boston, MA, 02111, USA. Kenneth.getz@tufts.edu.

Michael Wilkinson (M)

Tufts Center for the Study of Drug Development, Tufts University School of Medicine, 75 Kneeland Street, 11th Floor, Boston, MA, 02111, USA.

Jay Turpen (J)

The Avoca Group, Princeton, USA.

Dennis Salotti (D)

The Avoca Group, Princeton, USA.

Karen Rye (K)

AstraZeneca, Cambridge, UK.

Elspeth Carnan (E)

EMD Serono, Rockland, MA, USA.

Deborah Profit (D)

Otsuka Pharmaceutical Development and Commercialization, Princeton, USA.

Articles similaires

1.00
Humans Female Sick Leave Norway Sinusitis
Humans Mobile Applications Hepatitis C Male Female
Humans Male Female Health Knowledge, Attitudes, Practice Middle Aged
Humans Congenital Disorders of Glycosylation Female Male Surveys and Questionnaires

Classifications MeSH